Sinopharm executives face corruption probe in China

14 January 2014

China's largest drug distributor, state-owned Sinopharm, has become the most high profile domestic group to face corruption charges, which have so far largely focussed on foreign drug majors, most notably the UK’s GlaxoSmithKline (The Pharma Letters passim).

According to the latest reports, Sinopharm as said two of its former senior executives are being investigated over alleged corruption. A former vice president was detained by police last week, while a former general manager is also being probed.

In a statement filed with the Hong Kong stock exchange on Sunday, Sinopharm said its former vice president, Shi Jinming, had resigned last month for "personal reasons." It said he was detained last week by Shanghai prosecutors for "an investigation in relation to an allegation of corruption against him".

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK